- AnaptysBio (ANAB, Financial) to present updated Phase 2b RENOIR trial data for rosnilimab on June 3, 2025.
- Key experts involved include Dr. Paul Emery and Dr. Jonathan Graf.
- Company executives will participate in leading investor conferences following the data release.
AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company, has announced that it will release updated data from its global Phase 2b RENOIR clinical trial for rosnilimab, a PD-1+ T cells depleter and agonist, on June 3, 2025. The trial focuses on treating moderate-to-severe rheumatoid arthritis.
The investor call and webcast, scheduled for 4:15 pm ET, will feature contributions from distinguished medical experts, including Dr. Paul Emery from the University of Leeds and Dr. Jonathan Graf from UCSF, both of whom are involved in the RENOIR trial.
Following the data release, AnaptysBio's CEO Daniel Faga and other executive members will engage with investors at the Jefferies Global Healthcare Conference on June 5, and the Goldman Sachs Global Healthcare Conference on June 11, 2025. These events will include presentations, fireside chats, and one-on-one investor meetings.
Investors can view live webcasts of these events on AnaptysBio's website, where replays will be available for a minimum of 30 days post-event.
